In the German nNGM lung cancer cohort, a 26.2% ORR was reported in 61 HER2‐mutated NSCLC patients receiving ICI‐based therapy as the first‐line and later lines of treatment [20]. This evidence concerns the gene ERBB2 and lung cancer.